ROSWELL, Ga. and DUBLIN and HAMILTON, Bermuda, Dec. 7, 2021 /PRNewswire/ — Saol Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved Saol's Lyvispah (baclofen) oral granules. Lyvispah (lye-vis'-pah) is…Original Article
FDA Approves Lyvispah (baclofen) Oral Granules for the Treatment of Spasticity
